Plagrin75 mg

Acute Coronary Syndrome (ACS) — Requires Dual Antiplatelet Therapy with Aspirin

Plagrin is established for use in combination with aspirin to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with non-ST-segment elevation ACS (unstable angina/NSTEMI), including those managed medically and those undergoing percutaneous coronary intervention (PCI) with stent placement. In ST-elevation myocardial infarction (STEMI), Plagrin is used together with aspirin, with or without a loading dose depending on the treatment strategy. Monotherapy with Plagrin alone is not considered adequate in the acute-treatment phase of ACS; aspirin co-administration is guideline-directed unless aspirin is contraindicated.

Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Arterial Disease — Monotherapy

Plagrin is established as monotherapy (generally without routine aspirin combination) to reduce the composite rate of new ischemic stroke, new MI, and other vascular death in patients with a documented history of recent MI, recent ischemic stroke, or established peripheral arterial disease.

Post-Stent (Post-PCI) Use — Guideline-Supported Adjunct

Following coronary stent placement, Plagrin is used with aspirin as dual antiplatelet therapy (DAPT) to reduce the risk of stent thrombosis; the exact duration is individualized by the treating cardiologist based on stent type and bleeding versus ischemic risk (see Duration of Treatment).

Other Use — Not Routinely More Effective as Combination Therapy

In patients with a recent transient ischemic attack (TIA) or ischemic stroke who are not undergoing stenting, adding aspirin to Plagrin has not been shown to be more effective than Plagrin alone and increases the risk of major bleeding; this combination is not routinely recommended in that setting.

Each film-coated tablet contains 75 mg of Clopidogrel Bisulphate.

Plagrin is a prescription antiplatelet medicine that helps stop blood cells called platelets from clumping together to form clots. Doctors prescribe it to lower the chance of heart attack, stroke, and other serious circulation problems in people with acute coronary syndrome, a recent heart attack or stroke, peripheral arterial disease, or a recently placed coronary stent. It is taken as a tablet, usually once a day, and for some conditions it is combined with aspirin under a doctor's supervision. Because it affects how the blood clots, it also increases the chance of bleeding and needs to be used exactly as prescribed. Plagrin should never be started, stopped, or combined with other medicines without medical advice.

Antiplatelet Agent (P2Y12 Inhibitor / Thienopyridine)

Clopidogrel Bisulphate is an inactive prodrug that requires biotransformation, principally by the hepatic CYP2C19 enzyme (with contribution from other CYP isoenzymes), into an active thiol metabolite. This active metabolite irreversibly binds to the P2Y12 class of ADP receptors on the platelet surface, which blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex and thereby inhibits platelet aggregation for the remaining lifespan of the platelet (approximately 7–10 days). Because activation depends on CYP2C19, individuals who are poor metabolizers at this enzyme (genetically or due to a CYP2C19-inhibiting drug) generate less active metabolite and have a reduced antiplatelet effect — see Interactions and Precautions. Dose-dependent inhibition of platelet aggregation can be measured from about 2 hours after a single oral dose.

• Take Plagrin by mouth exactly as prescribed, at the same time each day.
• May be taken with or without food.
• Swallow the tablet whole with a glass of water; do not crush or chew unless advised.
• If a dose is missed, take it as soon as remembered on the same day; do not double the next dose to make up for a missed one.
• Do not stop taking Plagrin on your own, even if you feel well — stopping early, especially after a stent, can increase the risk of a heart attack or stent blockage.
• Tell every doctor, dentist, and pharmacist that you are taking Plagrin before any surgery, dental work, or new medicine (including over-the-counter products).

• CYP2C19-inhibiting drugs (omeprazole, esomeprazole, and similar proton pump inhibitors) — reduced effectiveness, use with caution: Plagrin must be activated by the liver enzyme CYP2C19 to work. Omeprazole and esomeprazole inhibit CYP2C19 and can significantly reduce formation of the active metabolite, lowering the antiplatelet effect of Plagrin — this is a prominent, well-documented safety concern and concurrent use should generally be avoided; if acid suppression is needed, an alternative with less CYP2C19 inhibition (e.g., pantoprazole) may be considered by the prescriber. This risk is compounded in people who are also genetic CYP2C19 poor metabolizers (see Precautions and Warnings).
• NSAIDs (e.g., ibuprofen, naproxen) — increased bleeding risk: Chronic co-administration increases the risk of gastrointestinal bleeding; use together only if the prescriber decides the benefit outweighs the risk.
• Anticoagulants (warfarin, heparin, and other blood thinners) — increased bleeding risk: Combined use increases the risk of serious bleeding and is generally avoided unless specifically indicated and closely monitored.
• Other antiplatelet agents and SSRIs/SNRIs — additive bleeding risk: Combining Plagrin with other antiplatelet drugs, or with SSRI/SNRI antidepressants that also affect platelet function, can further increase bleeding risk.
• Repaglinide and other CYP2C8 substrates — altered drug levels: A metabolite of Plagrin inhibits CYP2C8 and can raise blood levels of repaglinide; concurrent use is generally avoided.

Common Side Effects

• Easy bruising and minor bleeding (e.g., nosebleeds, gum bleeding)
• Prolonged bleeding from cuts
• Diarrhea and other gastrointestinal discomfort
• Skin rash or itching

Serious Side Effects — Seek Medical Attention Immediately

• Signs of significant or uncontrolled bleeding: blood in stool or urine, black/tarry stools, vomiting blood or material resembling coffee grounds, coughing up blood, or any bleeding that does not stop (see Precautions and Warnings for the full bleeding-risk explanation).
• Signs of thrombotic thrombocytopenic purpura (TTP) — a rare but serious blood disorder: fever, unusual bruising or purple skin spots, extreme tiredness, confusion or other neurological changes, and yellowing of the skin/eyes. This requires urgent emergency care.
• Signs of a severe allergic reaction: swelling of the face/lips/tongue/throat, difficulty breathing, or severe skin reaction (blistering, peeling skin).
• Signs of liver problems: yellowing of the skin or eyes, dark urine, severe fatigue.
• Signs of a serious blood cell disorder: unusual paleness, persistent fever, or repeated infections.

Pregnancy

There are no adequate and well-controlled studies of Plagrin in pregnant women, so its effects in human pregnancy are not well established. Animal reproduction studies have not shown evidence of harm to the fetus, but animal data do not always predict human outcomes. Plagrin should be used during pregnancy only if a physician determines the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether Plagrin or its metabolites pass into human breast milk. Because many drugs are excreted in breast milk and the effect on a nursing infant is unknown, a decision should be made with a physician to either discontinue breastfeeding or discontinue the medicine, taking into account the importance of treatment to the mother.

• Bleeding risk (most important safety concern): Plagrin increases the risk of bleeding, including serious and, rarely, fatal bleeding, because it reduces the blood's ability to clot. Patients should watch for unusual bruising, prolonged bleeding from cuts, blood in stool/urine, or black stools, and seek medical care promptly if these occur. If antiplatelet effect is not desired for an elective surgery or procedure with a major bleeding risk, Plagrin should be discontinued about 5 days beforehand, only on a doctor's instruction — never stop it yourself without medical guidance, since premature discontinuation (especially after a coronary stent) can increase the risk of a heart attack or stroke.
• Reduced effectiveness in CYP2C19 poor metabolizers (boxed-warning-level concern): Plagrin must be converted to its active form by the CYP2C19 liver enzyme. People who are genetically 'poor metabolizers' of CYP2C19 form less active drug and may get less protection against heart attack and stroke than patients with normal CYP2C19 function; this effect can be compounded by CYP2C19-inhibiting medicines such as omeprazole (see Interactions for the full explanation). This information is provided to explain the source of the warning; no specific genetic-testing recommendation is made here beyond what a treating physician may advise.
• Thrombotic thrombocytopenic purpura (TTP): A rare but serious and potentially fatal blood disorder has been reported, sometimes after short-term use. It requires prompt recognition and urgent treatment (often plasmapheresis) — seek emergency care immediately for fever, unusual bruising, extreme tiredness, confusion, or yellowing of the skin/eyes.
• Do not stop treatment without medical advice: Premature discontinuation increases the risk of cardiovascular events, particularly in patients with a recent coronary stent.
• Hypersensitivity and cross-reactivity: Rare allergic reactions, including angioedema and serious skin reactions, have been reported; patients with a history of thienopyridine allergy should discuss alternatives with their doctor.

An overdose of Plagrin most commonly leads to bleeding-related effects, since platelet inhibition from this medicine cannot be quickly reversed and lasts for the remaining lifespan of the affected platelets. Specific toxic-dose thresholds have not been established. If an overdose is suspected: do not induce vomiting unless specifically directed to do so by a doctor or poison control center; contact emergency medical services or a poison control center immediately for guidance; seek prompt medical attention, especially if there is any sign of bleeding. A physician may consider platelet transfusion to help restore normal clotting if clinically needed.

Store below 30°C in a dry place, protected from light and moisture. Keep in the original packaging until ready to use, and keep out of the reach and sight of children. Do not freeze. Always follow the storage instructions printed on the product label/pack, as directions may vary by manufacturer.

Children

Safety and effectiveness of Plagrin in pediatric patients have not been established; use in children is not a routine, established indication. In a controlled trial (CLARINET) in neonates and infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary-artery shunt, Plagrin added to standard care did not demonstrate a clinical benefit over placebo.

Elderly

No dosage adjustment is required based on age alone; elderly patients made up a large proportion of participants in major clinical trials. Because bleeding risk may be more consequential in older adults, they should be monitored appropriately.

Renal Impairment

Clinical experience is limited in patients with severe renal impairment. In patients with moderate renal disease, reduced platelet inhibition has been observed compared with healthy individuals; use with appropriate caution.

Hepatic Impairment

No dosage adjustment is considered necessary in patients with hepatic impairment, though experience in severe hepatic disease is limited and bleeding risk should be borne in mind.

Duration of therapy with Plagrin is individualized by the treating physician and depends on the indication:

• Acute coronary syndrome / post-stent (with aspirin): Dual antiplatelet therapy is typically continued for at least several months up to about 12 months following the event or stent placement, per treating-physician/cardiology guidance, with the exact duration individualized based on stent type, bleeding risk, and ischemic risk; therapy may be shortened or extended in specific situations at the physician's discretion.
• Recent MI, recent stroke, or established peripheral arterial disease (monotherapy): Often continued long-term/indefinitely, as determined by the prescribing physician based on ongoing cardiovascular risk.

Plagrin should never be stopped early without first consulting the prescribing doctor.

Antiplatelet agents; Thienopyridines; P2Y12 receptor inhibitors

Clopidogrel Bisulphate's active metabolite selectively and irreversibly binds to the P2Y12 subtype of ADP receptors on the platelet surface. This blocks ADP-induced activation of the GPIIb/IIIa receptor complex, which is required for platelet aggregation, thereby inhibiting platelet-to-platelet clumping for the remaining lifespan of the affected platelets (approximately 7–10 days), since the binding is irreversible.

Safety and effectiveness of Plagrin have not been established in pediatric patients. This is not a routine or established use in children; a controlled trial (CLARINET) found no clinical benefit of Plagrin over placebo in neonates and infants with cyanotic congenital heart disease palliated with a shunt. Use in children should only occur under specialist supervision where a physician judges it necessary.